INTRODUCTION {#s1}
============

Thyroid cancer is the most common endocrine malignancy, and its incidence has rapidly increased (more than 5% per year in both men and women). An estimated 64300 new thyroid cancer cases were diagnosed in the United States in 2016 according to Siegel et al. \[[@R1]\]. However, whether the increasing incidence of thyroid cancer is a result of the growing frequency of cancer detection procedures, such as high-resolution ultrasound, or is an actual increase in incidence is still controversial. Despite this uncertainty, the increasing rate of thyroid cancer is becoming a concerning issue.

Thyroid cancer has many histological subtypes; the most common of which are papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although many studies have focused on the morphological and clinicopathological risks as well as prognosis of PTC and FTC \[[@R2]--[@R9]\], mixed subtype thyroid cancer (MSTC), that is, adenocarcinoma combined with other types of carcinoma in the thyroid have rarely been investigated.

The Surveillance, Epidemiology, and End Results (SEER) Program has been established by the National Cancer Institute and is supported by the Surveillance Research Program to reduce the cancer burden, including that of thyroid cancer, among the US population. The SEER is a premier source of cancer surveillance data as well as analytical tools and is a leader in methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based statistics.

In this study, we investigated the prognosis, that is, cancer-specific mortality and all-cause mortality, of MSTC compared with PTC and FTC using propensity score matching based on the SEER database. Our finding would provide a reference for further understanding and treatment of MSTC.

RESULTS {#s2}
=======

Demographic and clinical features {#s2_1}
---------------------------------

This study assessed data from 98888 patients with thyroid cancer to analyze the prognosis of MSTC. Of these patients, 92963 had PTC, 5865 had FTC, and 60 had MSTC. The mean age and follow-up duration according to different histological subtypes are shown in Table [1](#T1){ref-type="table"}. No significant differences were noted in terms of the age between patients with MSTC and those with PTC or FTC.

###### Characteristics for Patients with different histological types

  Covariate                 level                                                       Histological types                                          
  ------------------------- ----------------------------------------------------------- -------------------- -------------- --------- ------------- ---------
  Age (year)                                                                            53.66±18.13          49.36±15.29    0.085     51.33±17.20   0.397
  Sex                       Female                                                      46(76.7%)            71785(77.2%)   0.919     4137(70.5%)   0.300
                            Male                                                        16(23.3%)            21178(22.8%)             1728(29.5%)   
  Race                      White                                                       49(81.7%)            76038(82.9%)   0.033     4529(78.3%)   0.471
                            Black                                                       8(13.3%)             5704(6.2%)               695(12.0%)    
                            Other                                                       3(5.0%)              9987(10.9%)              558(9.7%)     
  T stage                   T1                                                          17(28.8%)            55606(62.2%)   \<0.001   1283(23.8%)   \<0.001
                            T2                                                          12(20.3%)            13811(15.5%)             2174(40.2%)   
                            T3                                                          17(28.8%)            16407(18.4%)             1747(32.4%)   
                            T4                                                          13(22.1%)            3463(3.9%)               194(3.6%)     
  N-stage                   N0                                                          42(72.4%)            69465(79.0%)   0.218     5370(97.0%)   \<0.001
                            N1                                                          16(27.6%)            18460(21.0%)             168(3.0%)     
  M-stage                   M0                                                          52(91.2%)            89658(98.8%)   \<0.001   5377(94.2%)   0.334
                            M1                                                          5(8.8%)              1132(1.2%)               329(5.8%)     
  Multifocality             No                                                          28(50.0%)            52324(58.3%)   0.205     4735(85.6%)   \<0.001
                            Yes                                                         28(50.0%)            37350(41.7%)             797(14.4%)    
  Extension                 No                                                          37(62.7%)            75994(83.7%)   \<0.001   5114(90.5%)   \<0.001
                            Yes                                                         22(37.3%)            14847(16.3%)             539(9.5%)     
  Radiation                 None or refused                                             23(38.3%)            46761(51.5%)   0.006     2573(45.0%)   0.211
                            Radiation Beam or Rdioactive implants                       4(6.7%)              1705(1.9%)               177(3.1%)     
                            Radioisotopes or Radiation beam plus isotopes or implants   33(55.0%)            42296(46.6%)             2970(51.9%)   
  Surgery                   Lobectomy                                                   6(10.3%)             12688(14.2%)   \<0.001   1300(23.6%)   0.037
                            Subtotal or near-total thyroidectomy                        2(3.4%)              3337(3.7%)               303(5.5%)     
                            Total thyroidectomy                                         50(86.2%)            73162(82.1%)             3911(70.9%)   
  Survival months (month)                                                               41.63±37.44          49.09±33.76    0.041     53.12±34.33   0.006

MSTC: mixed subtype thyroid cancer; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma.

Cancer-specific and all-cause mortality rates of different histological subtypes {#s2_2}
--------------------------------------------------------------------------------

Upon follow-up on December 2013, the number of cancer-specific death was 7 in the MSTC group, 996 in the PTC group, and 190 in the FTC group. The cancer-specific mortality rates per 1000 person-years for MSTC, PTC, and FTC were 28.823 (95% confidence interval \[CI\]: 12.949--64.156), 2.403 (95% CI: 2.252--2.564), and 6.509 (95% CI: 5.598--7.569), respectively (Table [2](#T2){ref-type="table"}). In addition, during the follow-up period, the number of patients who died from all-cause death in the MSTC, PTC, and FTC group was 11, 4388, and 538, respectively. The all-cause mortality rates per 1000 person-years for MSTC, PTC, and FTC were 48.038 (95% CI: 25.8547--89.281), 11.068 (95% CI: 10.739--11.408), and 19.337 (95% CI: 17.717--21.104), respectively (Table [2](#T2){ref-type="table"}).

###### Hazard Ratios of different histological types for the cancer specific deaths and all cause deaths of thyroid cancer

  Histological types   Cancer-Specific Deaths,   \%     Cancer-Specific Deaths per   95% CI          All Cause Deaths,   \%      All Cause Deaths per   95% CI
  -------------------- ------------------------- ------ ---------------------------- --------------- ------------------- ------- ---------------------- ---------------
  MSTC                 7                         11.7   28.823                       12.949-64.156   11                  18.33   48.038                 25.847-89.281
  PTC                  966                       1.04   2.403                        2.252-2.564     4388                4.72    11.068                 10.739-11.408
  FTC                  190                       3.24   6.509                        5.598-7.569     538                 9.17    19.337                 17.717-21.104

MSTC: mixed subtypes thyroid cancer; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma.

Risk factors for cancer-specific and all-cause mortality {#s2_3}
--------------------------------------------------------

The results of the univariate Cox regression analyses demonstrated that cancer-specific mortality was associated with age; sex; race; histological type; tumor, node, and metastases (TNM) stage; extension; radiation treatment; and surgical approach. Moreover, all-cause mortality was also found to be associated with age, sex, race, histological type, TNM stage, multifocality, extension, radiation treatment, and surgical approach. Meanwhile, multivariate Cox regression model showed that histological subtypes were not an independent risk factor for cancer-specific and all-cause mortality (Table [3](#T3){ref-type="table"}).

###### Risk factors for survival: outcome of thyroid cancer specific mortality and all-cause mortality

  Covariate            Level                                                Thyroid Cancer specific mortality   All cause mortality                                                                                             
  -------------------- ---------------------------------------------------- ----------------------------------- --------------------- ---------------------- --------- ----------------------- --------- ---------------------- ---------
  Age                                                                       1.097(1.092-1.102)                  \<0.001               1.067(1.061-1.073)     \<0.001   1.087(1.085-1.089)      \<0.001   1.077(1.074-1.080)     \<0.001
  Sex                  Female                                               ref                                                       ref                              ref                               ref                    
                       Male                                                 2.765(2.463-3.103)                  \<0.001               1.407(1.201-1.647)     \<0.001   2.466(2.330-2.609)      \<0.001   1.662(1.549-1.783)     \<0.001
  Race                 White                                                ref                                                       ref                              ref                               ref                    
                       Black                                                1.077(0.853-1.359)                  0.533                 1.129(0.803-1.586)     0.486     1.295(1.170-1.435)      \<0.001   1.417(1.248-1.608)     \<0.001
                       Other                                                1.472(1.249-1.733)                  \<0.001               0.896(0.712-1.129)     0.353     0.958(0.872-1.053)      0.375     0.791(0.698-0.896)     \<0.001
  histological types   MSTC                                                 ref                                                       ref                              ref                               ref                    
                       PTC                                                  0.077(0.037-0.163)                  \<0.001               0.474(0.151-1.489)     0.201     0.221(0.123-0.400)      \<0.001   0.494(0.221-1.105)     0.086
                       FTC                                                  0.229(0.108-0.487)                  \<0.001               0.866(0.271-2.767)     0.808     0.400(0.220-0.726)      0.003     0.623(0.0.277-1.401)   0.252
  T-stage T-stage      T1                                                   ref                                                       ref                              ref                               ref                    
                       T2                                                   2.881(2.164-3.836)                  \<0.001               2.145(1.524-3.020)     \<0.001   1.087(0.992-1.191)      0.075     1.093(0.982-1.217)     0.102
                       T3                                                   7.763(6.173-9.763)                  \<0.001               3.574(2.494-5.122)     \<0.001   1.580(1.461-1.709)      \<0.001   1.168(1.015-1.343)     0.030
                       T4                                                   86.012(69.700-106.142)              \<0.001               13.459(8.952-20.234)   \<0.001   7.577(6.999-8.203)      \<0.001   2.687(2.233-3.233)     \<0.001
  N stage              N0                                                   ref                                                       ref                              ref                               ref                    
                       N1                                                   4.661(4.104-5.293)                  \<0.001               1.992(1.658-2.393)     \<0.001   1.662(1.555-1.777)      \<0.001   1.497(1.364-1.644)     \<0.001
  M-stage              M0                                                   ref                                                       ref                              ref                               ref                    
                       M1                                                   50.222(44.405-56.800)               \<0.001               6.865(5.691-8.281)     \<0.001   13.519(12.422-14.713)   \<0.001   3.926(3.435-4.488)     \<0.001
  Multifocality        No                                                   ref                                                       ref                              ref                               ref                    
                       Yes                                                  0.893(0.783-1.019)                  0.092                 0.781(0.666-0.915)     0.002     0.883(0.830-0.939)      \<0.001   0.968(0.901-1.041)     0.38
  Extension            No                                                   ref                                                       ref                              ref                               ref                    
                       Yes                                                  12.895(11.270-14.755)               \<0.001               1.574(1.137-2.178)     0.006     2.603(2.446-2.770)      \<0.001   1.121(0.958-1.310)     0.153
  Radiation            None or refused                                      ref                                                       ref                              ref                               ref                    
                       Radiation Beam or Rdioactive implants                14.149(12.142-16.486)               \<0.001               2.964(2.335-3.763)     \<0.001   3.460(3.109-3.850)      \<0.001   1.496(1.280-1.747)     \<0.001
                       Radioisotopes or Radiation beam+ isotopes/implants   0.902(0.790-1.030)                  0.126                 0.825(0.682-0.996)     0.046     0.584(0.550-0.621)      \<0.001   0.696(0.644-0.753)     \<0.001
  Surgery              Lobectomy                                            ref                                                       ref                              ref                               ref                    
                       Subtotal or near-total thyroidectomy                 1.896(1.355-2.653)                  \<0.001               1.190(0.786-1.801)     0.412     1.023(0.880-1.190)      0.764     1.021(0.862-1.209)     0.812
                       Total thyroidectomy                                  1.385(1.118-1.717)                  0.003                 1.041(0.793-1.367)     0.772     0.820(0.755-0.889)      \<0.001   0.967(0.879-1.064)     0.493

MSTC: mixed subtypes thyroid cancer; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma;

Adjusting for patient characteristics using propensity score matching {#s2_4}
---------------------------------------------------------------------

Without matching any factors, the cancer-specific and all-cause mortality rates between that of MSTC and that of PTC and FTC were significantly different (both p \< 0.001, Figure [1A--1D](#F1){ref-type="fig"}). Thus, to minimize selection bias, propensity score matching (PSM) was performed for age, sex, race, TNM stage, multifocality, extension, and radiation treatment. After PSM for demographic data, such as age, sex, and race, the cancer-specific mortality rate between MSTC and PTC and FTC decreased (p=0.195 and 0.067, respectively; Figure [2A, 2B](#F2){ref-type="fig"}). After PSM for age, sex, race, and clinicopathological features (TNM stage, multifocality, and extension), the cancer-specific mortality rate between MSTC and PTC and FTC was still not significantly different (p=0.077 and p=0.260, respectively; Figure [3A, 3B](#F3){ref-type="fig"}). After PSM for all relevant factors including radiation and surgery treatment, the cancer-specific mortality rate for MSTC remained not significantly different compared with PTC (p=0.077) and FTC (p=0.242) (Figure [4A, 4B](#F4){ref-type="fig"}).

![Kaplan Meier curves among patients stratified by subtype for cancer-specific mortality **(A, B)** and all-cause mortality **(C, D)**.](oncotarget-08-86556-g001){#F1}

![Kaplan Meier curves of cancer-specific mortality for matched subtype pairs\
Age, sex and race matching between MSTC and PTC **(A)**, MSTC and FTC **(B)**.](oncotarget-08-86556-g002){#F2}

![Kaplan Meier curves of cancer-specific mortality for matched subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matched between MSTC and PTC **(A)**, MSTC and FTC **(B)**.](oncotarget-08-86556-g003){#F3}

![Kaplan Meier curves of cancer-specific mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension, surgery and radiation treatment matched between MSTC and PTC **(A)**, MSTC and FTC **(B)**.](oncotarget-08-86556-g004){#F4}

After PSM for demographic data (age, sex, and race), the all-cause mortality rate for MSTC was similar to that of PTC and FTC (p=0.457 and 0.153, respectively; Figure [5A, 5B](#F5){ref-type="fig"}). However, after PSM for age, sex, race, and clinicopathological factors (TNM stage, multifocality, and extension) (Figure [6A, 6B](#F6){ref-type="fig"}), MSTC showed a lower all-cause survival than PTC (p=0.009) and a similar all-cause survival compared with FTC (p=0.183). similar results were obtained after PSM for all relevant factors including radiation and surgery treatment: MSTC was associated with a lower all-cause survival rate compared with PTC (p=0.009) and a similar all-cause survival when compared with FTC (p=0.079) (Figure [7A, 7B](#F7){ref-type="fig"}).

![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
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![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matching between MSTC and PTC **(A)**, MSTC and FTC **(B)**.](oncotarget-08-86556-g006){#F6}

![Kaplan Meier curves of all-cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension, surgery and radiation treatment matching between MSTC and PTC **(A)**, MSTC and FTC **(B)**.](oncotarget-08-86556-g007){#F7}

DISCUSSION {#s3}
==========

The histogenetic and pathogenetic origin of MSTC has been a topic of interest and has remained controversial. Volante et al. suggested "the hostage hypothesis" that stipulates that MSTC originate from different cells \[[@R10]\]. In their study, they suggested that MSTC are not derived from a single stem cell because the clonality analysis shows that different subtypes exhibit different patterns of molecular mutations and X-chromosomal inactivation.

In addition, whether MSTC has unique biologic behaviors compared with other subtypes is still unclear. Currently, only few investigations focus on the prognosis of MSTC \[[@R10]-[@R12]\]. Furthermore, the discussion of the American Thyroid Committee guideline on the biological behavior, molecular features, and prognosis of MSTC is limited.

In our study, analysis results of information obtained from the SEER database showed that histological subtype was not an independent factor for cancer-specific and all-cause mortality rates of MSTC. Before matching risk factors, MSTC had worse cancer-specific and all-cause mortality compared with PTC and FTC. However, after matching for all influencing factors, including radiation treatment, MSTC had similar prognosis to PTC and FTC. These results indicate that if patients with MSTC had similar demographic features, clinicopathological factors, and radiation treatment with those of patients with PTC and FTC, the survival rate would not be significantly different. Such results would be helpful for clinicians during the decision-making process.

One dilemma of MSTC is the diagnosis by fine-needle aspiration cytology. For example, mixed medullary-follicular thyroid carcinoma characterized by coexistence of morphological features of both follicular thyroid cancer and medullary thyroid cancer. It is difficult to identify without immunocytochemical examinations. When fine-needle aspiration cytology is preferred to diagnose such malignancy, adequate specimen and determination of serum calcitonin and thyroglobulin levels would be help for establishing an accurate diagnosis \[[@R13]-[@R17]\].

Notably, whether the type of treatment, including surgical approaches and radiation, affects the prognosis of MSTC still lacks adequate evidence \[[@R10]-[@R12], [@R17]-[@R20]\]. In our study, radiation was more frequently performed in patients with MSTC (61.7%) than in patients with PTC (48.5%). Moreover, MSTC patients (86.2%) were more likely to undergo total thyroidectomy than patients with PTC (82.1%) and FTC (70.9%). Therefore, the similar cancer-specific mortality of MSTC to PTC and FTC after matching for treatment approaches may suggest that patients with MSTC require aggressive treatment. It means that the difference of cancer-specific mortality between MSTC and PTC, FTC was shrink down may due to the aggressive treatment of MSTC.

Our study has some limitations. First, the lack of information on recurrence may cause overestimation bias when evaluating cancer-specific and all-cause mortality. Furthermore, we cannot differentiate the specific subtypes. Clonality analysis of mixed type thyroid cancer was also not performed; thus, analysis for each type compared with PTC and FTC separately could not be performed. In addition, BRAF mutation, TERT promoter mutation, and other molecular markers were not investigated in our study or matched for analysis.

In conclusion, we have shown the prognosis of MSTC compared with PTC and FTC. Our result would be beneficial for developing a personalize and accurate treatment guideline and understanding of MSTC.

MATERIALS AND METHODS {#s4}
=====================

Ethical considerations, study population and data collection {#s4_1}
------------------------------------------------------------

This study's retrospective protocol was approved by Union hospital's ethical review board and complied with the ethical standards of the Declaration of Helsinki, as well as the relevant national and international guidelines.

The present study evaluated SEER data (2004--2013) from patients with thyroid cancer according to their subtype (MSTC, PTC, and FTC) using code C73.9 from the International Classification of Diseases for Oncology(i.e., thyroid, papillary, and/or follicular histology). The eligible diagnostic codes were: "papillary carcinoma", "papillary adenocarcinoma", "follicular adenocarcinoma", "papillary carcinoma, follicular variant", and "papillary & follicular adenocarcinoma" "adenocarcinoma with mixed subtypes". Cases without American Joint Committee on Cancer staging information (version 6) were excluded to ensure accurate analyses. Cases without information of follow up time were also excluded. The three histological subtypes were compared according to age, sex, race, TNM stage, multifocality, extension, and radiation treatment (i.e., none or refused, external beam radiation therapy, or RAI).

Statistical analyses {#s4_2}
--------------------

The quantitative variables were expressed as mean ± standard deviation (SD), while the categorical ones were presented as percentages. Patient survival curves for thyroid cancer-specific mortality and all-cause mortality were examined by Kaplan-Meier analyses with the log-rank test. Cox proportional hazard regression analyses were using to estimate hazard ratios and 95% CIs, in order to quantify the effects of the different histological subtypes on cancer-specific and all-cause mortality. PSM was also used to further adjust for potential baseline confounding factors. All p-values were 2-sided, and p-values \< .05 were considered significant. Analyses were performed using SPSS version 23.0, Stata/SE version 12 (Stata Corp.), and GraphPad Prism version 6 (GraphPad Software Inc.).
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